Roy Dennis Bloom, MBBCh.

faculty photo
Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine

Contact information
One Founders Pavilion
3400 Spruce Street
Philadelphia, Pa 19104-6144
Office: (215) 662-4643
Fax: (215) 615-0349
Education:
BSc (Physiology and Biochemistry)
University of Witwatersrand, 1980.
M.B.B.Ch.
University of Witwatersrand, 1983.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Kidney transplant outcomes, Post-transplant diabetes mellitus, hepatitis C in kidney transplantation

Description of Clinical Expertise

Kidney Transplantation

Selected Publications

Varga Alexandra N, Johnson David, Sawinski Deirdre L, Lim Mary Ann, Bloom Roy D, Abt Peter L, Goral Simin, Bleicher Melissa, Levine Matthew H, Naji Ali, Nazarian Susanna, Porrett Paige, Trofe-Clark Jennifer: Safety and Feasibility of Outpatient Rabbit Antithymocyte Globulin Induction Therapy Administration in Kidney Transplant Recipients. Pharmacotherapy Apr 2018.

McCauley M, Mussell A, Goldberg D, Sawinski D, Molina RN, Tomlin R, Doshi SD, Abt P, Bloom R, Blumberg E, Kulkarni S, Esnaola G, Shults J, Thiessen C, Reese PP.: Race, Risk, and Willingness of End-Stage Renal Disease Patients Without Hepatitis C Virus to Accept an HCV-Infected Kidney Transplant. Transplantation 102(4): e163-e170, April 2018.

Lim MA, Kamili S, Cohen JB, Green-Montfort T, Tejada-Strop A, Kohli J, Drobeniuc J, Patel P, Vanderveen M, Bloom RD.: Hepatitis E Virus Infection in Kidney Transplant Patients: A Single-Center Study. Transplantation 102(4): e126-e127, April 2018.

Trofe-Clark J, Brennan DC, West-Thielke P, Milone MC, Lim MA, Neubauer R, Nigro V, Bloom RD: Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate Release Tacrolimus versus Extended Release Tacrolimus in African American Kidney Transplant Recipients American Journal of Kidney Diseases 71(3): 315-326, March 2018.

Potluri VS, Bloom RD: Treating Hepatitis C Virus in Patients with Advanced CKD in the Real-World: Time to Refocus on What Our Real Treatment Goals Should Be. Kidney International (in press) 2018.

Levitsky J, Formica RN, Bloom RD, Charlton M, Curry M, Friedewald J, Friedman J, Goldberg D, Hall S, Ison M, Kaiser T, Klassen D, Klintmalm G, Kobashigawa J, Liapakis A, O'Conner K, Reese P, Shelat K, Stewart D, Terrault N, Theodoropoulos N, Trotter J, Verna E, Volk M: The American Society of transplantation consensus conference on the use of hepatitis C viremic donors in solid organ transplantation. American Journal of Transplantation 17(11): 2790-2802, November 2017.

Hogan JJ, Lim MA, Palmer MB, Bloom RD, Chung RT, Sise ME: Development of proteinuria and focal segmental glomerulosclerosis during direct acting antiviral therapy for hepatitis C virus infection. Hepatology 66(2): 658-660, August 2017.

Bloom RD, Bromberg JS, Poggio E, Bunnapradist S, Langone A, Sood P, Matas A, Mehta S, Sharfuddin A, Fischbach B, Narayanan M, Jordan S, Cohen D, Hiller D, Prasad P, Woodward R, Grskovic M, Sninsky J, Yee JP and Brennan DC: Cell-free DNA and Active Rejection in Kidney Allografts. Journal of the American Society of Nephrology 28(7): 2221-2232, July 2017.

Koyawala N, Silber JH, Rosenbaum PR, Wang W,Hill AS, Reiter JG, Niknam BA, Even-Shoshan O,Bloom RD, Sawinski D, Nazarian S, Trofe-Clark J, Lim MA, Schold J, Reese PP : Comparing outcomes between antibody induction therapies in kidney transplantation. Journal of the American Society of Nephrology 28(7): 2188-2220, July 2017.

Sawinski D, Patel N, Appolo B, Bloom RD: Use of HCV+ donors does not affect HCV clearance with directly acting antiviral therapy but shortens the wait time to kidney transplantation. Transplantation 101(5), May 2017.

back to top
Last updated: 05/29/2018
The Trustees of the University of Pennsylvania